Ocugen

Youtube Subscribe

Open: 0.45 Close: 0.46 Change: 0.01

11 things an AI found about Ocugen that you should know before investing.

Are looking for the most relevant information about Ocugen? Investor spend a lot of time searching for information to make investment decisions in Ocugen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ocugen are: Ocugen, Inc, company, OCGN, stock, Ocugens, price, and the most common words in the summary are: ocugen, stock, news, price, inc, vaccine, company, . One of the sentences in the summary was: Average price target for Ocogen is $4.90, which is 958.32% higher than current price. …

Concept Map

Semantic Network

Stock Summary

Ocugen, Inc. focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function. OCU200, a fusion protein.

Today's Summary

Ocugen (OCGN) stock jumped more than 15% today after jumping over 15%. Average price target for Ocogen is $4.90, which is 958.32% higher than current price. Ocugens price volatility has been higher than the market average.

Today's News

Ocugen, Inc. (OCGN) statistics & valuation metrics - stock analysis. Ocugens price volatility has been higher than the market average. Average price target for Ocogen is $4.90, which is 958.32% higher than current price. Ocugen (OCGN) stock jumped more than 15% today after jumping over 15%. The company is clearly progressing on several fronts with its pipeline programs. Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold on Covaxins clinical trials in US. Ocugen is a clinical-stage biotech company that has no revenue at the moment. Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) climbed as high as 14.2% on Thursday, to $1.29, shortly before noon. The COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial. Ocugen, Inc. Announces pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million. The offering is expected to generate gross proceeds from the sale of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber. Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. The company will participate in the Retinal Vascular Disease Drug Development. Ocugen shares sink 20% on public offering pricing - marketwatch.com. OCGN +3.00% SPX +1.30% DJIA +1.00% OCGN is a biotechnology company focused on discovering novel gene and cell therapies. Ocugen raised a total of $19.73M in its latest funding round. Investors include Paycheck Protection Program, Histogenics, Abdi Ibrahim, JSC Lancaster Group, Frank Leo and 4 more. Ocugen Inc currently holds about 101.6  M in cash with (60.08  M ) of positive cash flow from operations. 30% of Ocugens Inc outstanding shares are owned by third-party entities. OcUGEN Inc is significantly underperforming NYSE Composite. Ocugen Inc is mainly related to its market volatility and company specific events. The danger of trading Ocugens Inc is main related to market volatility. The most common way to measure risk is by using the Sharpe ratio.

Stock Profile

"Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania."

Keywords

This document will help you to evaluate Ocugen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ocugen are: Ocugen, Inc, company, OCGN, stock, Ocugens, price, and the most common words in the summary are: ocugen, stock, news, price, inc, vaccine, company, . One of the sentences in the summary was: Average price target for Ocogen is $4.90, which is 958.32% higher than current price. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #ocugen #stock #news #price #inc #vaccine #company.

Read more →

Youtube Subscribe

---